Grandfield & Dodd’s Intellia Therapeutics NTLA Stock Holding History

Grandfield & Dodd’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$631K	Buy	52,310 +2,630	+5%	+$32.9K	0.03%	135
2026 Q2	$841K	Buy	49,680 +1,250	+3%	+$17.5K	0.04%	124
2026 Q1	$621K	Buy	48,430 +210	+0.4%	+$2.68K	0.04%	131
2025 Q4	$433K	Sell	48,220 -2,570	-5%	-$35.4K	0.02%	152
2025 Q3	$877K	Buy	50,790 +2,085	+4%	+$25.7K	0.05%	114
2025 Q2	$457K	Buy	48,705 +60	+0.1%	+$493	0.03%	141
2025 Q1	$346K	Buy	48,645 +17,550	+56%	+$177K	0.02%	159
2024 Q4	$363K	Buy	31,095 +18,085	+139%	+$282K	0.02%	162
2024 Q3	$267K	Buy	+13,010	New	+$300K	0.02%	189

Other funds holding NTLA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Grandfield & Dodd's NTLA Position: Q3 2026 in Review

Grandfield & Dodd increased its Intellia Therapeutics (NTLA) stake by 5.3% in Q3 2026, buying an estimated $32.9K and bringing the position to 52,310 shares worth $631K. The position accounts for 0.03% of the portfolio, ranked #135.

Grandfield & Dodd first reported a position in NTLA in Q3 2024 and has held it in 9 quarters since. The position peaked at $877K in Q3 2025. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Grandfield & Dodd held 52,310 shares of Intellia Therapeutics worth $631K as of Q3 2026.
Grandfield & Dodd bought 2,630 Intellia Therapeutics shares in Q3 2026, an estimated $32.9K.
Intellia Therapeutics made up 0.03% of Grandfield & Dodd's portfolio in Q3 2026, its #135 holding.
Grandfield & Dodd first reported a position in Intellia Therapeutics in Q3 2024 and has held it in 9 quarters since.
Grandfield & Dodd's Intellia Therapeutics position peaked at $877K in Q3 2025.
156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Grandfield & Dodd's 13F filing for Q3 2026, filed 29 Oct 2026.